1,009 reports of this reaction
4.0% of all TIOTROPIUM BROMIDE INHALATION SPRAY reports
#3 most reported adverse reaction
COUGH is the #3 most commonly reported adverse reaction for TIOTROPIUM BROMIDE INHALATION SPRAY, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 1,009 FDA adverse event reports linking TIOTROPIUM BROMIDE INHALATION SPRAY to COUGH. This represents approximately 4.0% of all 25,050 adverse event reports for this drug.
Patients taking TIOTROPIUM BROMIDE INHALATION SPRAY who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COUGH is moderately reported among TIOTROPIUM BROMIDE INHALATION SPRAY users, representing a notable but not dominant share of adverse events.
In addition to cough, the following adverse reactions have been reported for TIOTROPIUM BROMIDE INHALATION SPRAY:
The following drugs have also been linked to cough in FDA adverse event reports:
COUGH has been reported as an adverse event in 1,009 FDA reports for TIOTROPIUM BROMIDE INHALATION SPRAY. This does not prove causation, but indicates an association observed in post-market surveillance data.
COUGH accounts for approximately 4.0% of all adverse event reports for TIOTROPIUM BROMIDE INHALATION SPRAY, making it one of the most commonly reported side effect.
If you experience cough while taking TIOTROPIUM BROMIDE INHALATION SPRAY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.